Short answer
Celcuity Inc. (CELC) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). FDA approval of REVTORPYK™ (gedatolisib) for specified HR+/HER2- advanced or metastatic breast cancer patients.
Celcuity Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA approval of REVTORPYK™ (gedatolisib) for specified HR+/HER2- advanced or metastatic breast cancer patients
- Label targets patients without a detected PIK3CA mutation after progression on endocrine therapy
- Approval creates a commercial opportunity in metastatic breast cancer, subject to launch execution and adoption
- Company webcast and conference call scheduled July 14, 2026 at 4:30 p.m. CT for approval details
Item 8.01 · Other Events
- FDA approved REVTORPYK for HR+/HER2- advanced or metastatic breast cancer without PIK3CA mutation
- Commercial launch anticipated in late Q3 2026, creating potential near-term product revenue
- sNDA planned for Q3 2026 targeting PIK3CA-mutated breast cancer after endocrine therapy
- Expansion opportunity depends on FDA review and Phase 3 VIKTORIA-1 mutant-cohort results
Item EX-99.1 · Exhibit EX-99.1
- FDA approval makes REVTORPYK Celcuity’s first commercial product for HR+/HER2-, PIK3CA wild-type advanced breast cancer
- VIKTORIA-1 triplet reduced progression or death risk 76%; median PFS 9.3 months versus 2.0 months
- Doublet reduced progression or death risk 67%; median PFS 7.4 months versus 2.0 months
- Commercial launch targeted for late Q3 2026, creating near-term execution and commercialization milestones
- Safety burden remains material, including stomatitis in 72% of triplet patients and Grade 3 stomatitis in 22%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celcuity Inc. 8-K filings
Get the next CELC 8-K as it lands
Follow CELC for push alerts, or ask the research agent what this filing means.